Turtle Creek Wealth Advisors LLC Raises Stock Position in Stryker Corporation $SYK

Turtle Creek Wealth Advisors LLC grew its stake in Stryker Corporation (NYSE:SYK) by 11.7% in the 1st quarter, Holdings Channel reports. The firm owned 26,107 shares of the medical technology company’s stock after purchasing an additional 2,731 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in Stryker were worth $8,579,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of SYK. VanderPol Investments L.L.C. raised its stake in Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares in the last quarter. KCM Investment Advisors LLC boosted its position in Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after acquiring an additional 28 shares in the last quarter. Rossby Financial LCC grew its holdings in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares during the period. Stonebridge Capital Advisors LLC grew its holdings in shares of Stryker by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after acquiring an additional 29 shares during the period. Finally, Tcfg Wealth Management LLC raised its position in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last quarter. 4.60% of the stock is owned by insiders.

Stryker Stock Performance

Stryker stock opened at $326.41 on Friday. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $125.13 billion, a P/E ratio of 37.78, a PEG ratio of 2.01 and a beta of 0.77. The stock’s 50 day moving average is $309.86 and its 200 day moving average is $338.96.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the previous year, the firm posted $2.84 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Truist Financial reiterated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Canaccord Genuity Group reduced their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and an average target price of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.